Product Description
CP-690,550 is an oral, selective, potent inhibitor of the JAK family of enzymes.
Mechanisms of Action: JAK1 Inhibitor, JAK2 Inhibitor, JAK3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Arthritis, Rheumatoid|Colitis, Ulcerative
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Healthy Volunteers |
None |
|||
| A3921115 | P1 |
Completed |
Arthritis, Rheumatoid |
2010-03-01 |
2019-03-19 |
Treatments |
|
| A3921063 | P2 |
Completed |
Colitis, Ulcerative |
2010-09-01 |
2019-03-18 |
Treatments |
|
| 2004-002846-36 | P2 |
Completed |
Arthritis, Rheumatoid |
2006-06-20 |
2022-03-12 |
Treatments |
|
| OCTAVE | P3 |
Completed |
Colitis, Ulcerative |
2016-05-27 |
2019-03-19 |
Treatments |
|
| A3921064 | P3 |
Completed |
Arthritis, Rheumatoid |
2011-03-01 |
2019-03-18 |
Treatments |